| Assessment Status |
Rapid Review Complete |
| HTA ID |
26046 |
| Drug |
Ripretinib |
| Brand |
Qinlock® |
| Indication |
Ripretinib (Qinlock®) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. |
| Rapid review commissioned |
15/09/2026 |
| Rapid review completed |
30/09/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ripretinib compared with the current standard of care. |
